- Stock: Out Of Stock
- Brand: ACI Pharmaceuticals
- Product ID: Olmesartan Medoxomil
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
This Item is for pre order
Abetis 10mg Tablet — Olmesartan Medoxomil | Beximco Pharmaceuticals
| Generic Name | Olmesartan Medoxomil 10mg |
| Drug Class | Angiotensin II Receptor Blocker (ARB) |
| Manufacturer | Beximco Pharmaceuticals Ltd. |
| Route | Oral (Tablet) |
| Prescription Status | Prescription Required |
Overview
Abetis 10mg contains Olmesartan Medoxomil, a potent and selective Angiotensin II Type 1 (AT1) receptor blocker (ARB). Olmesartan is one of the most efficacious ARBs available and is a preferred antihypertensive in diabetic patients due to its renoprotective properties. It is first-line therapy for hypertension in Type 2 diabetes with or without diabetic nephropathy. The 10mg dose is used for initiation or in patients requiring lower doses.
Mechanism of Action
Olmesartan is a prodrug hydrolysed to its active form (RNH-6270) after oral absorption. It selectively and insurmountably blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction, aldosterone secretion, sodium retention, and renal afferent arteriolar constriction. This results in vasodilation, reduced blood pressure, and reduced intraglomerular pressure — slowing progression of diabetic nephropathy.
Indications
- Hypertension — all stages, as monotherapy or in combination
- Diabetic nephropathy — renoprotection in Type 2 diabetics with microalbuminuria or proteinuria
- Prevention of cardiovascular events in high-risk hypertensive patients
Dosage
| Indication | Starting Dose | Maintenance | Maximum |
|---|---|---|---|
| Hypertension | 10–20mg once daily | 20mg once daily | 40mg once daily |
| Diabetic nephropathy | 20mg once daily | 20–40mg once daily | 40mg once daily |
| Elderly / volume-depleted | 10mg once daily | 10–20mg | 40mg |
Take with or without food at the same time each day. Full blood pressure-lowering effect achieved within 2 weeks.
Critical Diabetic Patient Information
- Renoprotection: ARBs like olmesartan reduce urinary albumin excretion and slow diabetic nephropathy progression. All diabetics with hypertension and/or microalbuminuria should be on an ARB or ACE inhibitor
- Monitor potassium: Olmesartan reduces aldosterone — risk of hyperkalaemia especially in CKD. Check K⁺ within 1–2 weeks of starting and every 3–6 months
- Monitor renal function: A rise of up to 25–30% in creatinine after starting is expected and acceptable. Greater rises may indicate bilateral renal artery stenosis
- Do NOT combine with ACE inhibitor or aliskiren — dual RAS blockade increases risk of hyperkalaemia, hypotension, and renal failure
Side Effects
| System | Side Effect | Severity |
|---|---|---|
| Renal | Elevated creatinine (initial, often stabilises) | Common — usually acceptable |
| Electrolytes | Hyperkalaemia (especially in CKD) | Moderate — monitor |
| Cardiovascular | Hypotension, dizziness (first dose) | Common — Mild |
| GI | Olmesartan-associated enteropathy (rare) | Rare — Moderate |
| Respiratory | No cough (advantage over ACE inhibitors) | — |
| Serious (rare) | Angioedema | Rare — Serious |
Drug Interactions
| Drug | Interaction |
|---|---|
| ACE inhibitors | Do not combine — dual RAS blockade |
| Aliskiren | Contraindicated in diabetics |
| Potassium-sparing diuretics / supplements | Risk of hyperkalaemia |
| NSAIDs | Reduce antihypertensive effect; increase nephrotoxicity |
| Antidiabetic drugs | ARBs may improve insulin sensitivity — monitor glucose |
| Lithium | Increased lithium toxicity — monitor levels |
Contraindications
- Pregnancy (second and third trimester)
- Known hypersensitivity to olmesartan
- Combination with aliskiren in diabetics or eGFR <60
- Bilateral renal artery stenosis
Storage
Store below 30°C. Protect from light and moisture. Keep out of reach of children.
Frequently Asked Questions
Q: Why are ARBs preferred in diabetics?
A: ARBs block the renin-angiotensin system, which is overactive in diabetes. They reduce intraglomerular pressure, decrease proteinuria, and slow diabetic nephropathy — benefits not shared by other antihypertensive classes at equivalent BP reduction.
Q: My creatinine rose slightly after starting Abetis — is this normal?
A: A rise up to 25–30% is expected and kidney-protective long term. Inform your physician if the rise exceeds this.
Medical Disclaimer: Abetis 10mg (Olmesartan Medoxomil) is a prescription-only medicine. Contraindicated in pregnancy. Monitor renal function and potassium after starting. Do not combine with ACE inhibitors or aliskiren. This information is for educational purposes only. Always follow your physician's instructions.
